PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors.
Our key offerings include:
Transactions / deal negotiations;
Product / technology valuations;
Deal term advice;
Due diligence & expert reports;
Strategy formulation;
Alliance management; and
Expert opinion for litigation/arbitration cases.
PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
EUSA Pharma
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology , oncology supportive care and critical care products.
The company currently has nine products on the market, including Erwinase and Kidrolase for treatment of acute lymphoblastic leukemia , Caphosol for the treatment of oral mucositis , a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, the antibiotic surgical implant Collatamp, ProstaScint for imaging the extent and spread of prostate cancer , and Quadramet for the treatment of pain in patients whose cancer has spread to the bones. EUSA Pharma also has several products in late-stage development, notably Leukotac, a monoclonal antibody in phase III development for treatment of steroid resistant acute Graft versus Host Disease (aGvHD).
Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and oncology supportive care business of Innocoll Pharmaceuticals Inc.
As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $2 billion company by the middle of this decade.